Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Genetic and epigenetic regulation of the organic cation transporter 3, SLC22A3.

Chen L, Hong C, Chen EC, Yee SW, Xu L, Almof EU, Wen C, Fujii K, Johns SJ, Stryke D, Ferrin TE, Simko J, Chen X, Costello JF, Giacomini KM.

Pharmacogenomics J. 2013 Apr;13(2):110-20. doi: 10.1038/tpj.2011.60. Epub 2012 Jan 10.

2.

Identification and characterization of novel polymorphisms in the basal promoter of the human transporter, MATE1.

Ha Choi J, Wah Yee S, Kim MJ, Nguyen L, Ho Lee J, Kang JO, Hesselson S, Castro RA, Stryke D, Johns SJ, Kwok PY, Ferrin TE, Goo Lee M, Black BL, Ahituv N, Giacomini KM.

Pharmacogenet Genomics. 2009 Oct;19(10):770-80. doi: 10.1097/FPC.0b013e328330eeca.

3.

Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver.

Nies AT, Koepsell H, Winter S, Burk O, Klein K, Kerb R, Zanger UM, Keppler D, Schwab M, Schaeffeler E.

Hepatology. 2009 Oct;50(4):1227-40. doi: 10.1002/hep.23103.

PMID:
19591196
4.

Functional genetic variation in the basal promoter of the organic cation/carnitine transporters OCTN1 (SLC22A4) and OCTN2 (SLC22A5).

Tahara H, Yee SW, Urban TJ, Hesselson S, Castro RA, Kawamoto M, Stryke D, Johns SJ, Ferrin TE, Kwok PY, Giacomini KM.

J Pharmacol Exp Ther. 2009 Apr;329(1):262-71. doi: 10.1124/jpet.108.146449. Epub 2009 Jan 13.

5.

Epigenetic regulation of CpG promoter methylation in invasive prostate cancer cells.

Mathews LA, Hurt EM, Zhang X, Farrar WL.

Mol Cancer. 2010 Oct 7;9:267. doi: 10.1186/1476-4598-9-267.

6.

Different involvement of promoter methylation in the expression of organic cation/carnitine transporter 2 (OCTN2) in cancer cell lines.

Qu Q, Qu J, Zhan M, Wu LX, Zhang YW, Lou XY, Fu LJ, Zhou HH.

PLoS One. 2013 Oct 16;8(10):e76474. doi: 10.1371/journal.pone.0076474. eCollection 2013.

7.

Increased heparanase expression is caused by promoter hypomethylation and up-regulation of transcriptional factor early growth response-1 in human prostate cancer.

Ogishima T, Shiina H, Breault JE, Tabatabai L, Bassett WW, Enokida H, Li LC, Kawakami T, Urakami S, Ribeiro-Filho LA, Terashima M, Fujime M, Igawa M, Dahiya R.

Clin Cancer Res. 2005 Feb 1;11(3):1028-36.

8.

Hypoexpression and epigenetic regulation of candidate tumor suppressor gene CADM-2 in human prostate cancer.

Chang G, Xu S, Dhir R, Chandran U, O'Keefe DS, Greenberg NM, Gingrich JR.

Clin Cancer Res. 2010 Nov 15;16(22):5390-401. doi: 10.1158/1078-0432.CCR-10-1461. Epub 2010 Nov 9.

9.

EFEMP1 as a novel DNA methylation marker for prostate cancer: array-based DNA methylation and expression profiling.

Kim YJ, Yoon HY, Kim SK, Kim YW, Kim EJ, Kim IY, Kim WJ.

Clin Cancer Res. 2011 Jul 1;17(13):4523-30. doi: 10.1158/1078-0432.CCR-10-2817. Epub 2011 May 13.

10.

Downregulation of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) in human hepatocellular carcinoma and their prognostic significance.

Heise M, Lautem A, Knapstein J, Schattenberg JM, Hoppe-Lotichius M, Foltys D, Weiler N, Zimmermann A, Schad A, Gründemann D, Otto G, Galle PR, Schuchmann M, Zimmermann T.

BMC Cancer. 2012 Mar 22;12:109. doi: 10.1186/1471-2407-12-109.

11.

Role of organic cation transporter 3 (SLC22A3) and its missense variants in the pharmacologic action of metformin.

Chen L, Pawlikowski B, Schlessinger A, More SS, Stryke D, Johns SJ, Portman MA, Chen E, Ferrin TE, Sali A, Giacomini KM.

Pharmacogenet Genomics. 2010 Nov;20(11):687-99. doi: 10.1097/FPC.0b013e32833fe789.

12.

Association between gene polymorphisms of SLC22A3 and methamphetamine use disorder.

Aoyama N, Takahashi N, Kitaichi K, Ishihara R, Saito S, Maeno N, Ji X, Takagi K, Sekine Y, Iyo M, Harano M, Komiyama T, Yamada M, Sora I, Ujike H, Iwata N, Inada T, Ozaki N.

Alcohol Clin Exp Res. 2006 Oct;30(10):1644-9.

PMID:
17010131
13.

Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer.

Henrique R, Costa VL, Cerveira N, Carvalho AL, Hoque MO, Ribeiro FR, Oliveira J, Teixeira MR, Sidransky D, Jerónimo C.

J Mol Med (Berl). 2006 Nov;84(11):911-8. Epub 2006 Sep 22.

PMID:
17016690
14.

Functional analysis of human organic cation transporter OCT3 (SLC22A3) polymorphisms.

Sakata T, Anzai N, Kimura T, Miura D, Fukutomi T, Takeda M, Sakurai H, Endou H.

J Pharmacol Sci. 2010;113(3):263-6. Epub 2010 Jun 16.

15.

Identification and characterization of proximal promoter polymorphisms in the human concentrative nucleoside transporter 2 (SLC28A2).

Yee SW, Shima JE, Hesselson S, Nguyen L, De Val S, Lafond RJ, Kawamoto M, Johns SJ, Stryke D, Kwok PY, Ferrin TE, Black BL, Gurwitz D, Ahituv N, Giacomini KM.

J Pharmacol Exp Ther. 2009 Mar;328(3):699-707. doi: 10.1124/jpet.108.147207. Epub 2008 Dec 19.

16.

Epigenetic regulation of MDR1 gene through post-translational histone modifications in prostate cancer.

Henrique R, Oliveira AI, Costa VL, Baptista T, Martins AT, Morais A, Oliveira J, Jerónimo C.

BMC Genomics. 2013 Dec 17;14:898. doi: 10.1186/1471-2164-14-898.

17.

Tumor suppressor function of PGP9.5 is associated with epigenetic regulation in prostate cancer--novel predictor of biochemical recurrence after radical surgery.

Mitsui Y, Shiina H, Hiraki M, Arichi N, Hiraoka T, Sumura M, Honda S, Yasumoto H, Igawa M.

Cancer Epidemiol Biomarkers Prev. 2012 Mar;21(3):487-96. doi: 10.1158/1055-9965.EPI-11-0970. Epub 2012 Jan 13.

18.

Methylation of the ASC gene promoter is associated with aggressive prostate cancer.

Collard RL, Harya NS, Monzon FA, Maier CE, O'Keefe DS.

Prostate. 2006 May 15;66(7):687-95.

PMID:
16425203
19.

Epigenetic regulation of EFEMP1 in prostate cancer: biological relevance and clinical potential.

Almeida M, Costa VL, Costa NR, Ramalho-Carvalho J, Baptista T, Ribeiro FR, Paulo P, Teixeira MR, Oliveira J, Lothe RA, Lind GE, Henrique R, Jerónimo C.

J Cell Mol Med. 2014 Nov;18(11):2287-97. doi: 10.1111/jcmm.12394. Epub 2014 Sep 11.

20.

Candidate tumor suppressor gene SLC5A8 is frequently down-regulated by promoter hypermethylation in prostate tumor.

Park JY, Zheng W, Kim D, Cheng JQ, Kumar N, Ahmad N, Pow-Sang J.

Cancer Detect Prev. 2007;31(5):359-65. Epub 2007 Nov 26.

PMID:
18037591
Items per page

Supplemental Content

Write to the Help Desk